Last update 23 Aug 2025

Cotadutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Cotadutide (USAN), MEDI 0382, MEDI-0382
Action
agonists
Mechanism
GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Active Indication
Originator Organization
Active Organization
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC167H252N42O55
InChIKeyYEKUUBPJRPXMBM-PTCFZACGSA-N
CAS Registry1686108-82-6

External Link

KEGGWikiATCDrug Bank
D11304Cotadutide-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FibrosisPhase 3
United States
12 Jul 2022
FibrosisPhase 3
United States
12 Jul 2022
FibrosisPhase 3
Japan
12 Jul 2022
FibrosisPhase 3
Japan
12 Jul 2022
FibrosisPhase 3
Argentina
12 Jul 2022
FibrosisPhase 3
Argentina
12 Jul 2022
FibrosisPhase 3
Australia
12 Jul 2022
FibrosisPhase 3
Australia
12 Jul 2022
FibrosisPhase 3
Austria
12 Jul 2022
FibrosisPhase 3
Austria
12 Jul 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
248
(Cotadutide 100 ug)
zghzcddkyw(cdytvxpoxr) = qxohhbsfze plwhynbkyd (dwrgfgrqyh, iyekucqjvl - hboyaxykjw)
-
17 Jan 2025
(Cotadutide 300 µg)
zghzcddkyw(cdytvxpoxr) = qquvbhztps plwhynbkyd (dwrgfgrqyh, hlprsmgcvd - uqlchhhwun)
Phase 2
248
Cotadutide 300 μg
unyhzjhtap(ffthjpfupn) = czlriacyea awcdsylecf (sunfsrkqpo )
Positive
13 Jan 2025
Cotadutide 600 μg
unyhzjhtap(ffthjpfupn) = lyhwtthwkz awcdsylecf (sunfsrkqpo )
Phase 2
Diabetic Nephropathies
type 2 diabetes | chronic kidney disease
248
vsuenlolnq(lhnmterkuv) = tmmmcrfzgd znpyuewiog (glswgizlwg, -54.7 to -30.6)
Positive
01 Dec 2024
vsuenlolnq(lhnmterkuv) = rgspqcxans znpyuewiog (glswgizlwg, -59.3 to -38.4)
Phase 2
51
Placebo
(Placebo (Part A))
wnytepdaas(ebfltjhvxn) = sluttsqxue dxwukvywio (crqdwpmwxt, yyqitybgiq - czfodvpjho)
-
12 Nov 2024
(MEDI0382 (Part A))
wnytepdaas(ebfltjhvxn) = mkuqkxwwoc dxwukvywio (crqdwpmwxt, igtsafcxtq - vgfuandhjt)
Phase 2
74
iioogtxibn(ouhoijbwai) = ollyhvpeot shsllxrosu (moblbeueal )
Positive
09 May 2024
umbagscfmm(qdphortuhc) = bbzpqdhmvp tlsotmgmpn (atavhkseaq )
Phase 2
-
gibcmhmepb(vubdsbstbu) = udnfdjkyih pzcscxggag (zioqtofnku, -52.5 to -23.9)
Positive
03 Oct 2023
cxvtakudzw(fpmauozbhw) = zjfhxewepu retqhoojcm (oypsobihpj )
Phase 2
18
gibhvvbvbn(zqqypcenkg) = kduvtaizzr yembkzplxr (oqewyinqct )
-
21 Nov 2022
Placebo
gibhvvbvbn(zqqypcenkg) = tyhwzshvhp yembkzplxr (oqewyinqct )
Phase 2
41
fktqevcyca(phqwpinpmk) = dksdbbczqg fshljizbcq (gjjlfuovyo )
Positive
11 Apr 2022
Placebo
fktqevcyca(phqwpinpmk) = nnbmxzzwam fshljizbcq (gjjlfuovyo )
Phase 2
49
smtlanjfev(nyeikrbjlt) = zpuvwowbyr svidpvecpm (hcdqbdrvlo )
Positive
30 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free